HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies |
Kim, SoRa
(New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center)
Kim, Dae Hoon (New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center) Kim, Young-Seok (New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center) Ha, Tae-Young (New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center) Yang, Jin (New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center) Park, Soo Hyun (Bio-therapy Human Resources Center, Animal Medical Center and Department of Veterinary Physiology, College of Veterrinary Medicine, Chonnam National University) Jeong, Kwang Won (College of Pharmacy, Gachon University) Rhee, Jae-Keol (New Drug Discovery Lab., Hyundai Pharmaceutical Co. Ltd., Gyeong-Gi Bio-Center) |
1 | Yoshida, S., Tanaka, H., Oshima, H., Yamazaki, T., Yonetoku, Y., Ohishi, T., Matsui, T. and Shibasaki, M. (2010) AS1907417, a novel GPR119 agonist, as an insulinotropic and b-cell preservative agent for the treatment of type 2 diabetes. Biochem. Biophysis. Res. Commun. 400, 745-751. DOI |
2 | Amiel, S. A., Dixon, T., Mann, R. and Jameson, K. (2008) Hypoglycaemia in type 2 diabetes. Diabet. Med. 25, 245-254. DOI |
3 | Barnett, A. (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60, 1454-1470. DOI |
4 | Barnett, A., Allsworth, J., Jameson, K. and Mann, R. (2007) A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies. Curr. Med. Res. Opin. 23, 1493-1507. DOI |
5 | Bekur, R., Nagaraja, M. V., Shivashankara, K. N. and Stanley, W. (2010) Sitagliptin-induced hemolysis. Indian J. Pharmacol. 42, 320-321. DOI |
6 | Chu, Z. L., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., Unett, D., Liang, Y., Demarest, K., Semple, G., Behan, D. P. and Leonard, J. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609. DOI |
7 | DeFronzo, R. A., Bonadonna, R. C. and Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368. DOI ScienceOn |
8 | Furman, B., Pyne, N., Flatt, P. and O'Harte, F. (2004). Targeting beta-cell cyclic 3′5′ adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. J. Pharm. Pharmacol. 56, 1477-1492. DOI |
9 | Giorgino, F., Leonardini, A., Natalicchio, A. and Laviola, L. (2011) Multifactorial intervention in Type 2 diabetes: the promise of incretinbased therapies. J. Endocrinol. Invest. 34, 69-77. DOI |
10 | Ho, J., Leung, A. K. and Rabi, D. (2011) Hypoglycemic agents in the management of type 2 diabetes mellitus. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 66-73. DOI ScienceOn |
11 | Iltz, J. L., Baker, D. E., Setter, S. M. and Keith Campbell, R. (2006) Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clin. Ther. 28, 652-665. DOI ScienceOn |
12 | Jones, R. M. and Leonard, J. N. (2009) The emergence of GPR119 agonists as anti-diabetic agents. In Annual Reports in Medicinal Chemistry Vol 44 (J. E. Macor, Ed), pp149-170, Academic Press, Oxford. |
13 | Jones, R. M., Leonard, J. N., Buzard, D. J. and Lehmann, J. (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359. DOI |
14 | Katz, L. B., Gambale, J. J., Rothenberq, P. L., Vanapalli, S. R., Vann aro, N., Xi, L., Sarich, T. C. and Stein, P. P. (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, doubleblind, placebe-controlled studies in subjects with type 2 diabetes. Diabetes Obes. Metab. 14, 709-716. DOI |
15 | Raun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B. and Knudsen, L. B. (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-iv inhibitor, vildagliptin, does not. Diabetes 56, 8-15. DOI |
16 | Kreymann, B., Williams, G., Ghatei, M. A. and Bloom, S. R. (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 2, 1300-1304. |
17 | Iyer, S. N., Drake, A. J. 3rd, West, R. L., Mendez, C. E. and Tanenberg, R. J. (2012) Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr. Pract. 18, e10-13. DOI |
18 | Meece, J. (2007) Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr. Med. Res. Opin. 23, 933-944. DOI |
19 | Taylor, S. I., Accili, D. and Imai, Y. (1994) Insulin resistance or insulin deficiency: Which is the primary cause of NIDDM. Diabetes 43, 735-740. DOI |
20 | Winzell, M. S. and Ahren, B. (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53, S215-219. DOI ScienceOn |
21 | Yokota, K. and Igaki, N. (2012) Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: A case report. Intern. Med. 51, 2041-2044. DOI |
22 | Xia, Y., Chackalamannil, S., Greenlee, W. J., Jayne, C., Neustadt, B., Stamford, A., Vaccaro, H., Xu, X. L., Baker, H., O'Neill, K., Woods, M., Hawes, B. and Kowalski, T. (2011) Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for the type 2 diabetes. Bioorg. Med. Chem. Lett. 21, 3290-3296. DOI |
23 | Ross, S. A. and Ekoe, J. M. (2010). Incretin agents in type 2 diabetes. Can. Fam. Physician 56, 639-648. |
24 | Drucker, D. J., Jin, T., Asa, S. L., Young, T. A. and Brubaker, P. L. (1994) Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol. Endocrinol. 8, 1646-1655. |